To evaluate the efficacy and safety of SPH7485 tablets in patients with advanced solid tumors.
Histologically or cytologically confirmed advanced solid tumors；
At least one extracranial measurable lesion;
ECOG (Eastern Cooperative Oncology Group) performance status score of 0 or 1;
Subjects whose laboratory examination indicators meet the prescribed standards during the screening period;
Subjects who have received the prescribed other anti-tumor treatments at the prescribed time prior to the first dose;
Subjects who have received previous drugs with the same target;
Subjects with active infections requiring systemic treatment;
Subjects with third gap fluid accumulation that cannot be controlled by drainage or other methods;